ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Targeting the CRYAB/β-Catenin Axis with an MMP-9-Responsive Hydrogel Disrupts CTC Clusters to Suppress Progression of Hepatocellular Carcinoma after Radiofrequency Ablation.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Incomplete radiofrequency ablation (iRFA) represents a major clinical challenge in hepatocellular carcinoma (HCC) management, as residual tumors acquire enhanced metastatic potential through undefined mechanisms. Herein, we report that sublethal thermal stress upregulates the heat-responsive molecular chaperone CRYAB, which stabilizes β-catenin protein by inhibiting its ubiquitin-mediated proteasomal degradation. The CRYAB/β-catenin axis drives epithelial-mesenchymal transition (EMT) in residual HCC cells and simultaneously polarizes tumor-associated neutrophils (TANs) toward the pro-tumorigenic N2 phenotype. This dual regulation pre-programs a pro-metastatic microenvironment in situ, promotes the formation of heterotypic circulating tumor cell (CTC) clusters, and ultimately accelerates tumor recurrence and metastasis post-iRFA. To suppress this pathological cascade, we engineered a matrix metalloproteinase-9 (MMP-9)-responsive thermosensitive hydrogel system (XB@Gel) that enables localized and sustained co-delivery of the β-catenin inhibitor XAV-939 and the PD-L1 inhibitor BMS-202. XB@Gel effectively reverses EMT, reprograms the immunosuppressive microenvironment, reduces CTC clusters, and robustly inhibits HCC recurrence and metastasis after iRFA. Collectively, our findings identify the CRYAB/β-catenin axis as a key transducer of thermal stress into a pro-metastatic signaling cascade in residual HCC and establish XB@Gel as a promising multi-dimensional therapeutic strategy to combat post-iRFA progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.